

Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships

The American Society of Breast Surgeons 25th Annual Meeting

General Session

Friday, April 12 – Sunday, April 14, 2024

Orlando, FL

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](#), the ASBrS requires individuals in a position to control the educational content of a CME activity (including but not limited to, course/program chairs, moderators, faculty, authors, content reviewers, editors, planning committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity.

Individuals must review and adhere to the ASBrS CME Activity Policy and Disclosure Process as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—employees of ineligible companies can participate as planners or faculty in these specific situations:

- a. When the content of the activity is not related to the business lines or products of their employer/company.
- b. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.

- c. When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation –as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity.

All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards. The inability to mitigate an identified relevant relationship results in the participant’s withdrawal from participation in the CME activity.

A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual’s (in a position to control educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

Oversight

The CME Committee and Ethics Committees ensure that there is no commercial bias or influence in ASBrS CME activities. They work together to ensure proper conflict management. Members of these committees serve as additional oversight, participating and observing ASBrS CME activities to look for any evidence of bias and ensure compliance with the ASBrS policies.

Reporting Conflicts

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME and Ethics Committee at cme@breastsurgeons.org.

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The following individuals and groups have been involved in the planning, implementation, approval, evaluation, and/or oversight of this activity. All disclosed relationships are within the 24 months prior to their involvement with the CME activity. All relevant disclosed relationships have been mitigated by a designated CME Committee Official

<i>J. Michael Dixon, Professor, OBE, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Deborah Farr, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nathalie Johnson, MD</i>	<i>Speaker</i>	<i>1. Keliomics</i>	<i>1. Stock options; Advisory Board</i>	<i>Dr. Johnson's relationship with Keliomics (ownership interest) meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' Peer review of presentation content was also performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i>
<i>Sarah McLaughlin, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Roshni Rao, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

Lorraine Tafra, MD	Moderator	<ol style="list-style-type: none"> 1. AL Gore 2. Breast Care Architects 	<ol style="list-style-type: none"> 1. Fee for consulting; Consultant 2. Fee for services; Founding Partner (Owner) 	<p>The Breast Care Architects (Owner) relationship meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.'</p> <p>The session faculty were selected by the annual meeting program chair to address broader implications and recommendations. The other financial relationship is not relevant the role.</p>
Helen Pass, MD	Speaker	<ol style="list-style-type: none"> 1. Exact Sciences 2. Endomag 	<ol style="list-style-type: none"> 1. Honorarium; Speaker 2. Honorarium; Speaker 	Financial relationships are not relevant to role
Paul Baron, MD	Moderator	None	N/A	N/A
Michele Carpenter, MD	Speaker	<ol style="list-style-type: none"> 1. Perimeter Medical 	<ol style="list-style-type: none"> 1. Training and Honorarium; Advisory and education 	<p>The financial relationship is relevant to the role. Peer review of presentation content was performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</p>
Anshumi Desai, MD	Speaker	None	N/A	N/A
Massimo Ferrucci, MD, PhD	Speaker	None	N/A	N/A
Nicketti Handy, MD	Speaker	None	N/A	N/A

<i>Katrina Mitchell, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Courtney Vito, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Michael Alvarado, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Patrick Borgen, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Mahmoud El-Tamer, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Carla Fisher, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Julie Margenthaler, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Katherine Kopkash, MD</i>	<i>Speaker</i>	<ol style="list-style-type: none"> 1. <i>SimBioSys</i> 2. <i>Exact Sciences</i> 3. <i>Vector Surgical</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Consultant (Relationship Ended)</i> 2. <i>Honorarium; Advisory Board (Relationship Ended)</i> 3. <i>Honorarium; Consultant (Relationship Ended)</i> 	<i>Financial relationship(s) are not relevant to the role.</i>
<i>Eric Manahan, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. <i>Astrazeneca</i> 2. <i>Aptitude Health</i> 3. <i>Myriad Genetics</i> 4. <i>Elucent</i> 5. <i>Endomag</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Speakers bureau</i> 2. <i>Honorarium; Consultant/Speaker</i> 3. <i>Honorarium; Speaker</i> 4. <i>Honorarium; Speaker/consultant</i> 5. <i>Honorarium; Speaker</i> 	<i>Financial relationship(s) are not relevant to the role.</i>

<i>Helen Pass, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none">1. <i>Exact Sciences</i>2. <i>Endomag</i>	<ol style="list-style-type: none">1. <i>Honorarium; speaker</i>2. <i>Honorarium; speaker</i>	<i>Financial relationship(s) are not relevant to the role.</i>
-----------------------	------------------	--	---	--

<p><i>Shawna Willey, MD</i></p>	<p><i>Speaker</i></p>	<ol style="list-style-type: none"> 1. <i>Videra Surgical</i> 2. <i>EndoMagnetics</i> 3. <i>Lumicell</i> 4. <i>Pacira Pharmaceuticals</i> 5. <i>Medtronic</i> 6. <i>Hologic</i> 7. <i>TransMed 7</i> 8. <i>TME/Aptitude</i> 9. <i>Myriad</i> 10. <i>Cairn Surgical</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Speaker (Relationship Ended)</i> 2. <i>Honorarium, Travel expenses; Speaker</i> 3. <i>Honorarium; Member, DSMB</i> 4. <i>Honorarium, Travel expenses; Speaker</i> 5. <i>Honorarium, Travel expenses; Speaker</i> 6. <i>Honorarium, Travel expenses; Speaker, consultant</i> 7. <i>Nothing; Scientific Adviser (Ownership Interest)</i> 8. <i>Honorarium, Travel expenses; Consultant</i> 9. <i>Honorarium; Focus Group Member (Relationship Ended)</i> 10. <i>Food&Beverage; Scientific Advisory Board</i> 	<p><i>The TransMed 7 (ownership interest) relationship is not relevant to the role. Dr. Willey meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.'</i></p> <p><i>The other financial relationships are not relevant to the role.</i></p>
---------------------------------	-----------------------	---	---	--

<i>Katharine Yao, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Akiko Chiba, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Beth DuPree, MD</i>	<i>Speaker</i>	<ol style="list-style-type: none"> 1. <i>Medtronic</i> 2. <i>Perimeter Medical</i> 3. <i>Prelude Dx</i> 4. <i>InnerStill Health</i> 5. <i>Signal Relief</i> 6. <i>Gateway Sciences</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Speaker</i> 2. <i>Honorarium, Stock options; Consultant, independent contractor</i> 3. <i>Honorarium; Speaker</i> 4. <i>Equity; Medical Director (Ownership Interest)</i> 5. <i>Honorarium; Medical director</i> 6. <i>Nothing; Medical Director</i> 	<i>Dr. DuPree's relationships with InnerStill Health, Signal Relief, and Gateway Sciences (ownership interest; Medical Director) meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' The other financial relationships are not relevant to the role. Peer review of presentation content was also performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i>
<i>Lillian Erdahl, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Camelia Lawrence, MD</i>	<i>Speaker</i>	<ol style="list-style-type: none"> 1. <i>Hologic</i> 2. <i>Myriad Genetic</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Consultant</i> 2. <i>Honorarium; Advisor</i> 	<i>Financial relationships are not relevant to the role.</i>

<i>Stephanie Serres, MD, PhD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jennifer Tseng, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. <i>Intuitive Surgical</i> 2. <i>Elucent</i> 	<ol style="list-style-type: none"> 1. <i>Research Funding; Site PI for Clinical Trial (Relationship Ended)</i> 2. <i>Travel Expenses; Training Course (Relationship Ended)</i> 	<i>Financial relationships are not relevant to the role.</i>
<i>Zahraa Al-Hilli, MD, MBA</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Ronda Henry-Tillman, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jane Mendez, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Lisa Newman, MD, MPH</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kristin Rojas, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Preya Ananthakrishnan, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Marissa Howard-McNatt, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Henry Kuerer, MD, PhD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>William Sikov, MD</i>	<i>Speaker</i>	<ol style="list-style-type: none"> 1. <i>Lilly Oncology</i> 2. <i>Seagen</i> 3. <i>DaiichiSankyo</i> 	<ol style="list-style-type: none"> 1. <i>Honoraria; Honoraria and speaker's training for promotional presentations (Relationship Ended)</i> 2. <i>Honoraria; Honoraria and speaker's training for promotional presentations (Relationship Ended)</i> 3. <i>Honoraria; Honoraria and speaker's training for promotional presentations (Relationship Ended)</i> 	<i>All financial relationships are relevant. Educational content has been peer reviewed the CME committee; clinical recommendations are free of commercial bias and the content of the presentation does not actively promote commercial material.</i>
<i>Bret Taback, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Julia White, MD, FACR, FASTRO</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>David Gruen, MD, MBA, FACR</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Judy Boughey, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. <i>Eli Lilly</i> 2. <i>SymBioSis</i> 3. <i>CairnsSurgical</i> 4. <i>UptoDate</i> 5. <i>PER and PeerView</i> 6. <i>EndoMag</i> 	<ol style="list-style-type: none"> 1. <i>Research funding (institute); Researcher</i> 2. <i>Research funding; Consultant</i> 3. <i>Expenses; DSMB</i> 4. <i>Royalties; royalties</i> 5. <i>Honorarium; speaker (Relationship Ended)</i> 6. <i>Travel, accomodation, honorarium; speaker (Relationship Ended)</i> 	<i>The financial relationships are not relevant to the role.</i>
<i>Carinne Anderson, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Sarah Blair, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Katherina Calvillo, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kristalyn Gallagher, DO, FACOS, FACS</i>	<i>Moderator</i>	<i>1. Endomag/Mammotome</i>	<i>1. Honorarium; Participated in a peer to peer conversation</i>	<i>Relationship is not relevant to role.</i>
<i>Manpreet Kohli, MD</i>	<i>Moderator</i>	<i>1. Impedimed</i>	<i>1. Honorarium; Oncology Advisory Board Committee Member</i>	<i>Relationship is not relevant to role.</i>
<i>Ekaterini Tsiapali, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Nora Hansen, MD</i>	<i>Moderator</i>	<i>1. Merck</i>	<i>1. Honorarium; Speaker's forum</i>	<i>Financial relationship is not relevant to role.</i>
<i>Kelly Hunt, MD</i>	<i>Speaker</i>	<i>1. Armada Health 2. AstraZeneca 3. Cairn Surgical 4. Eli Lilly & Co. 5. Lumicell</i>	<i>1. Stipend; Medical Advisory Board 2. Stipend; Medical Advisory Board 3. Funding to my institution; Researcher 4. Research funding to my institution; Researcher (Relationship Ended) 5. Research funding to my institution; Researcher</i>	<i>Financial relationships are not relevant to role.</i>

<i>E. Shelley Hwang, MD, MPH</i>	<i>Speaker</i>	<ol style="list-style-type: none"> 1. <i>Exai bio</i> 2. <i>Lumicell</i> 3. <i>Clinetic</i> 	<ol style="list-style-type: none"> 1. <i>Stock options; Advisory board</i> 2. <i>Travel; Advisory board</i> 3. <i>Steering committee</i> 	<i>Dr. Hwang's financial relationship with Exai Bio (stock ownership) meets ACCME exception: 'a. When the content of the activity is not related to the business lines or products of their employer/company.' The other relationships are not relevant to her role.</i>
<i>Julia White, MD, FACR, FASTRO</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Cory Donovan, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jay Harness, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. <i>Medtronic Enabling Technology</i> 2. <i>Lumicell</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Speaker (Relationship Ended)</i> 2. <i>Honorarium; Chair-Data Safety Monitoring Board</i> 	<i>Financial relationships are not relevant to the role.</i>
<i>Jessica Maxwell, MD</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. <i>Dilon Technologies</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Advisory Board</i> 	<i>Financial relationship is not relevant to the role.</i>
<i>Taryn Smith, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Israel Falade</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Massimo Ferrucci, MD, PhD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Kush Lohani</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Julie Margenthaler, MD, FACS</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Tesia McKenzie, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Anna Stachura, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Preeti Subhedar, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Paul Thiruchelvam, MD, PhD, FRCS</i>	<i>Moderator</i>	<ol style="list-style-type: none"> 1. Stryker 2. Endomagnetics 3. Cytoveris 	<ol style="list-style-type: none"> 1. Honorarium; Speaker fee 2. Honorarium; Speaker fee 3. Nothing; Consultant 	<i>Financial relationships are not relevant to the role.</i>
<i>Danielle Thompson, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Elle Clelland</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Peter Fasching, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

Andreas Giannakou, MD	Speaker	None	N/A	N/A
Nimmi Kapoor, MD, FACS	Speaker	None	N/A	N/A
Keva Li	Speaker	None	N/A	N/A
Mara Piltin, DO	Speaker	1. Intuitive Surgical	1. Research funding (institute -FDA IDE clinical trial for robotic mastectomy)	Financial relationship is not relevant to role.
Julia Tchou, MD, PhD	Moderator	1. BD	1. Consultation fees; Consultant	Financial relationship is not relevant to role.
Mediget Teshome, MD	Moderator	1. Endomagnetics, LTD	1. Travel, accommodations, food; Conference Support (Relationship Ended)	Financial relationship is not relevant to role.
Vivian Bea, MD, MBS, FACS	Speaker	1. Pfizer 2. Allergan Aesthetics	1. Grant (Relationship Ended) 2. Consultant	The relationships are not relevant to the role.
Lisa Curcio, MD	Moderator	None	N/A	N/A
David Euhus, MD	Speaker	None	N/A	N/A

Kevin Hughes, MD	Moderator	<ol style="list-style-type: none"> 1. Volpara 2. Hologic 3. TME - Targeted Medical Education 4. Invitae (Genetics company) 5. 23&Me 6. CRA Health (Formerly Hughes RiskApps) 	<ol style="list-style-type: none"> 1. Honorarium; Speaker (Relationship Ended) 2. Honoraria/consulting fees; Speaker/Consultant 3. Honoraria/consulting fees; Speaker/consultant - genetics education and consulting (Relationship Ended) 4. Honoraria/consulting fees; Speaker/consultant 5. Honoraria/consulting fees; Speaker/consultant 6. Founder (Ownership Interest) 	<p>Dr. Hughes' financial relationships are relevant to the role. His relationship with CRA Health (Ownership interest) meets ACCME exception 2. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, they do not make care recommendations). However, he is functioning as the moderator of the session and has no prepared slides. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations.</p>
Jennifer Plichta, MD, MS	Speaker	None	N/A	N/A
Steven Cai, MD	Moderator	<ol style="list-style-type: none"> 1. Hologic 2. PreludeDX 	<ol style="list-style-type: none"> 1. Honorarium; Consultant, speaker 2. Honorarium; Consultant 	<p>All financial relationships are relevant to the role. However, he is functioning as the moderator of the session and has no prepared slides. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations.</p>
David Edmonson, MD	Speaker	<ol style="list-style-type: none"> 1. Impedimed 	<ol style="list-style-type: none"> 1. Honorarium; Surgical Advisory Board member 	<p>Financial relationship is not relevant to the role.</p>

Ted James, MD	Speaker	1. <i>Perimeter</i>	1. <i>Honorarium/Options; Advisory Board</i>	<i>Financial relationship is not relevant to the role.</i>
Sharon Lum, MD, MBA, FACS	Moderator	1. <i>Myriad</i> 2. <i>Intuitive</i> 3. <i>Medtronic</i>	1. <i>Honorarium; consultant (Relationship Ended)</i> 2. <i>Accommodations; Meeting participant (Relationship Ended)</i> 3. <i>Food&Beverage; Meeting participant (Relationship Ended)</i>	<i>Financial relationships are not relevant to the role.</i>
Patricia Clark, MD, FACS, FSSO	Moderator	1. <i>Integro</i> 2. <i>Endomag</i>	1. <i>Consulting fee; Advisor</i> 2. <i>Honorarium; Speaker</i>	<i>The financial relationships are not relevant to the role.</i>

<p><i>Jill Dietz, MD, MHCM</i></p>	<p><i>Speaker</i></p>	<p>1. <i>Peace Medical Consulting, LLC</i> 2. <i>Cyduct Diagnostics</i></p>	<p>1. <i>Honorarium and expenses and consulting fees; Part owner of this company. (Owner)</i> 2. <i>Options; Chief Medical Officer (Ownership Interest)</i></p>	<p><i>Dr. Dietz' relationships with Peace Medical Consulting and Cyduct Diagnostic (Owner and Employee) meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.'</i></p> <p><i>Peer review of presentation content was also performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</i></p>
<p><i>Sadia Khan, DO</i></p>	<p><i>Speaker</i></p>	<p><i>None</i></p>	<p><i>N/A</i></p>	
<p><i>Jessica Ryan, MD</i></p>	<p><i>Moderator</i></p>	<p><i>None</i></p>	<p><i>N/A</i></p>	
<p><i>William Scarlett, DO, MHCM, FACS, FACOS</i></p>	<p><i>Speaker</i></p>	<p>1. <i>Medtronic</i></p>	<p>1. <i>Honorarium; speaker</i></p>	<p><i>Financial relationship is not relevant to the role.</i></p>

<p>Stephanie Valente, DO, FACS</p>	<p>Speaker</p>	<ol style="list-style-type: none"> 1. Impedimed 2. Merit Medical 3. Pacira 4. AxoGen 5. Hologic 	<ol style="list-style-type: none"> 1. Honorarium; Advisory Board 2. Honorarium; Speaker (Relationship Ended) 3. Honorarium; Speaker (Relationship Ended) 4. Honorarium; Advisor 5. Honorarium; Course Speaker 	<p>Dr. Valente's financial relationship with Hologic is relevant to her roles.</p> <p>Peer review of presentation content was performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material. The other financial relationships are not relevant.</p>
<p>Michael Berry, MD</p>	<p>Speaker</p>	<ol style="list-style-type: none"> 1. TransMed7 2. Aptitude Health 3. Molli Medical 	<ol style="list-style-type: none"> 1. Consultant, Investor (Ownership Interest – relationship ended) 2. Honorarium; Consultant 3. Honorarium; Consultant 	<p>Dr. Berry's relationship with TransMed 7 (ownership interest) meets ACCME exceptions 'a. When the content of the activity is not related to the business lines or products of their employer/company.' The other financial relationships also are not relevant to the role. Peer review of presentation content was also performed by the CME committee. The presentation is free of commercial bias and the content of the presentation does not promote commercial material.</p>
<p>Chandler Cortina, MD, MS, FSSO, FACS</p>	<p>Speaker</p>	<p>None</p>	<p>N/A</p>	<p>N/A</p>

<i>Kandace McGuire, MD</i>	<i>Speaker</i>	<i>1. Mammutome, Inc</i>	<i>1. Honorarium; Advisory board, speaker</i>	<i>The financial relationship is not relevant to the role.</i>
<i>Jamie Patterson, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Theresa Schwartz, MD</i>	<i>Speaker</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kay Yoon-Flannery, DO, MPH, FACS</i>	<i>Moderator</i>	<i>1. Dilon Technologies</i>	<i>1. Honorarium; Consultant</i>	<i>The financial relationship is relevant to role. The session faculty were selected by the annual meeting program chair to address broader implications and recommendations.</i>
<i>Jennifer Gass, MD</i>	<i>Moderator</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Planners, Approvers, Regulatory, Oversight Committees and Staff</i>				
<i>Judy Boughey, MD</i>	<i>Planner (Annual Meeting Committee), Approver (Board of Directors)</i>	<i>1. Eli Lilly 2. SymBioSis 3. CairnsSurgical 4. UptoDate 5. PER and PeerView 6. EndoMag</i>	<i>1. Research funding (institute); Researcher 2. Research funding; Consultant 3. Expenses; DSMB 4. Royalties; royalties 5. Honorarium; speaker (Relationship Ended) 6. Travel, accommodation,</i>	<i>As planner and board of director member, Dr. Boughey recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).could occur related to their financial relationship(s).</i>

			<i>honorarium; speaker (Relationship Ended)</i>	<i>For planning, the CME committee also reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i>
<i>Marta Boyer,</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>David Brenin, MD</i>	<i>Approver (Board of Directors)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Katherina Calvillo, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Kjirsten Carlson, MD</i>	<i>Regulatory, Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Lynn Dengel, MD</i>	<i>Regulatory, Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<p><i>Jill Dietz, MD, MHCM</i></p>	<p><i>Planner (Annual Meeting Committee), Approver (Board of Directors)</i></p>	<p>1. <i>Peace Medical Consulting, LLC</i> 2. <i>Cyduct Diagnostics</i></p>	<p>1. <i>Honorarium and expenses and consulting fees; Part owner of this company. (Owner)</i></p> <p>2. <i>Options; Chief Medical Officer (Ownership Interest)</i></p>	<p><i>As planner and board of director member, Dr. Dietz recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i></p> <p><i>As planner, the relationships with Peace Medical Consulting and Cyduct Diagnostic (Owner and Employee) meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.'</i></p> <p><i>For planning, the CME committee also reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i></p>
<p><i>Meghan Flanagan, MD, MPH</i></p>	<p><i>Regulatory, Reviewer (CME Committee)</i></p>	<p><i>None</i></p>	<p><i>N/A</i></p>	<p><i>N/A</i></p>
<p><i>Jennifer Gass, MD</i></p>	<p><i>Planner (Annual Meeting Committee)</i></p>	<p><i>None</i></p>	<p><i>N/A</i></p>	<p><i>N/A</i></p>
<p><i>Janie Grumley, MD</i></p>	<p><i>Regulatory, Reviewer (CME Committee)</i></p>	<p><i>None</i></p>	<p><i>N/A</i></p>	<p><i>N/A</i></p>

<i>Regina Hampton, MD</i>	<i>Approver (Board of Directors)</i>	<i>1. Cherry Blossom Intimates, Inc.</i>	<i>1. Stock options; Co-owner, Vice President (Owner)</i>	<i>As a board of director member, Dr. Hampton recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Ronda Henry-Tillman, MD</i>	<i>Approver (Board of Directors)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Tina Hieken, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>1. Genentech 2. SkylineDX BV</i>	<i>1. Research Funding (Institution) 2. Research Funding (Institution)</i>	<i>As an Ethics committee member, Dr. Hieken recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Erica Holland</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<p><i>Kevin Hughes, MD</i></p>	<p><i>Approver (Board of Directors)</i></p>	<ol style="list-style-type: none"> 1. <i>Volpara</i> 2. <i>Hologic</i> 3. <i>TME - Targeted Medical Education</i> 4. <i>Invitae (Genetics company)</i> 5. <i>23&Me</i> 6. <i>CRA Health (Formerly Hughes RiskApps)</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; Speaker (Relationship Ended)</i> 2. <i>Honoraria/consulting fees; Speaker/Consultant</i> 3. <i>Honoraria/consulting fees; Speaker/consultant - genetics education and consulting (Relationship Ended)</i> 4. <i>Honoraria/consulting fees; Speaker/consultant</i> 5. <i>Honoraria/consulting fees; Speaker/consultant</i> 6. <i>Founder (Ownership Interest)</i> 	<p><i>As a board of director member, Dr. Hughes recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i></p>
<p><i>Nathalie Johnson, MD</i></p>	<p><i>Planner (Annual Meeting Committee), Approver (Board of Directors)</i></p>	<ol style="list-style-type: none"> 1. <i>Keliomics</i> 	<p><i>1. Stock options; Advisory Board</i></p>	<p><i>As planner and board of director member, Dr. Johnson recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i></p> <p><i>As planner, the Keliomics (stock options) relationship meets ACCME exception 'a. When the content of the activity is not related to the business lines or products of their employer/company.' For planning, the CME committee reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i></p>

<i>David Kaufman, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Brigid Killelea, MD, MPH, FACS</i>	<i>Planner (Annual Meeting Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jillian Lloyd, MD</i>	<i>Regulatory, Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Christina Lucara</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Eric Manahan, MD</i>	<i>Planner (Annual Meeting Committee), Approver (Board of Directors)</i>	<ol style="list-style-type: none"> 1. <i>Astrazeneca</i> 2. <i>TME</i> 3. <i>Myriad Genetics</i> 4. <i>Elucent</i> 5. <i>Endomag</i> 	<ol style="list-style-type: none"> 1. <i>Honorarium; speakers bureau</i> 2. <i>Honorarium; Consultant/Speaker</i> 3. <i>Honorarium; Speaker's Bureau</i> 4. <i>Honorarium; Speaker/consultant</i> 5. <i>Honorarium; Speaker</i> 	<p><i>As planner and board of director member, Dr. Manahan recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i></p> <p><i>For planning, the CME committee reviewed how topics and speakers were determined and obtained evidence that the topics represented a balanced, non-biased, evidence-based approach.</i></p>
<i>Cindy Matsen, MD, MSCI, FACS</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Sarah McLaughlin, MD</i>	<i>Regulatory, Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>

<i>Toan Nguyen, MD</i>	<i>Approver (Board of Directors)</i>	<i>1. Aptitude Health</i>	<i>1. Honorarium; consultant/advisor</i>	<i>As a board of director member, Dr. Nguyen recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Terry Sarantou, MD</i>	<i>Approver (Board of Directors)</i>	<i>1. TME (relationship ended)</i>	<i>1. Honorarium</i>	<i>As a board of director member, Dr. Sarantou recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Ranjna Sharma, MD</i>	<i>Regulatory, Reviewer (CME Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Puneet Singh, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>1. Physicians' Education Resource</i>	<i>1. Honoraria</i>	<i>As an Ethics committee member, Dr. Singh recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Sarah Tevis, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>
<i>Jennifer Tseng, MD</i>	<i>Oversight (Ethics Committee)</i>	<i>1. Intuitive Surgical</i>	<i>1. Site PI on mulitcenter clinical trial</i>	<i>As an Ethics committee member, Dr. Singh recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).</i>
<i>Tekoah White</i>	<i>Staff</i>	<i>None</i>	<i>N/A</i>	<i>N/A</i>